Cue Biopharma (CUE) Stock Statistics & Valuation Metrics

Cue Biopharma has a market cap or net worth of $56.71M. The enterprise value is $67.34M.

Cue Biopharma has 75,349,884 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cue Biopharma’s return on equity (ROE) is -1.37 and return on invested capital (ROIC) is -100.71%.

The current PE Ratio of Cue Biopharma is -2.38. Cue Biopharma’s PEG ratio is 0.10.

In the last 12 months, Cue Biopharma had revenue of 5.49M and earned -50.73M in profits. Earnings per share was -1.11.

In the last 12 months, operating cash flow was -38.26M and capital expenditures -64.00K, giving a free cash flow of -38.32M billion.

Cue Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Cue Biopharma upcoming earnings date is May 13, 2025, TBA Not Confirmed.

Cue Biopharma as a current ratio of 3.01, with Debt / Equity ratio of 37.50%

In the past 12 months, Cue Biopharma has paid 0.00 in taxes.

Cue Biopharma EV to EBITDA ratio is -1.89, with an EV/FCF ratio of -2.18.

Cue Biopharma has $32.42M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$22.91M billion.

Gross margin is -17.81%, with operating margin of -949.89%, and net profit margin of -924.10%.

The average price target for Cue Biopharma is $2.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy